Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
13F holders, Q4 2023
Institutional positions in Verona Pharma plc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- +15 vs. Q3 2023
- Shares held
- 67.6M
- +2.28M (+3.5%) vs. Q3 2023
- Total value
- $1.35B
- +$278.8M (+26.1%) vs. Q3 2023
- New holders
- 23
- 38 more added
- Sold out
- 8
- 32 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $359.0K |
| Q3 2025 | 243 | $8.57B |
| Q2 2025 | 292 | $7.18B |
| Q1 2025 | 258 | $4.58B |
| Q4 2024 | 191 | $3.19B |
| Q3 2024 | 150 | $1.95B |
| Q2 2024 | 125 | $957.0M |
| Q1 2024 | 113 | $1.08B |
| Q4 2023 | 117 | $1.35B |
| Q3 2023 | 102 | $1.07B |
| Q2 2023 | 105 | $1.33B |
| Q1 2023 | 95 | $1.21B |
| Q4 2022 | 88 | $1.31B |
| Q3 2022 | 68 | $529.0M |
| Q2 2022 | 40 | $145.9M |
| Q1 2022 | 39 | $181.7M |
| Q4 2021 | 42 | $248.0M |
| Q3 2021 | 40 | $202.7M |
| Q2 2021 | 37 | $239.9M |
| Q1 2021 | 37 | $305.1M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Verona Pharma plc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Turn Management, LLC | 1,206,291 | $24.0M | 3.44% | +1,206,291 | New |
| Eventide Asset Management, LLC | 1,377,781 | $27.4M | 0.45% | +527,781+62.1% | Added |
| Jennison Associates LLC | 1,585,385 | $31.5M | 0.02% | +142,819+9.9% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 1,656,492 | $32.9M | 0.68% | +1,656,492 | New |
| Janus Henderson Group PLC | 1,803,361 | $35.8M | 0.02% | +166,539+10.2% | Added |
| Octagon Capital Advisors LP | 2,369,000 | $47.1M | 7.54% | 00.0% | Unchanged |
| Carlyle Group Inc. | 2,457,500 | $48.8M | 2.35% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 2,493,530 | $49.6M | 0.12% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $59.9M | 3.20% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,187,415 | $63.4M | 2.22% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,777,778 | $75.1M | 1.50% | 00.0% | Unchanged |
| Wellington Management Group LLP | 3,783,994 | $75.2M | 0.01% | −683,577−15.3% | Reduced |
| Perceptive Advisors LLC | 3,866,214 | $76.9M | 1.72% | −140,983−3.5% | Reduced |
| Vivo Capital, LLC | 4,249,918 | $84.5M | 6.92% | 00.0% | Unchanged |
| FMR LLC | 4,902,377 | $97.5M | 0.01% | −2,055,581−29.5% | Reduced |
| NEA Management Company, LLC | 5,108,563 | $111.0M | 7.40% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 6,317,990 | $125.6M | 1.96% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −926,432−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −47,800−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −13,500−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −12,516−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,607−100.0% | Sold out |
| Cahill Wealth Management, LLC | 0 | $0 | 0.00% | −10,445−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −10,024−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −212−100.0% | Sold out |